Extending the shelf life of fruit: Ugandan entrepreneurs Sandra Namboozo and Samuel Muyita in top 10 innovators of the Young Inventors Prize 2025
Food loss and waste account for 8-10% of annual global greenhouse gas emissions, according to the UNFCCC
Namboozo and Muyita's sachets keep fruit fresh by up to extra 30 days, reducing waste and boosting farmer incomes
The pair are among top ten innovators for the Young Inventors Prize, awarded by the European Patent Office (EPO) on 18 June 2025
MUNICH, May 13, 2025 /PRNewswire/ -- Over 1 billion tonnes of food are wasted annually, while 783 million people face hunger, according to the United Nations Framework Convention on Climate Change (UNFCCC). Ugandan entrepreneurs Sandra Namboozo (26) and Samuel Muyita (27), founders of Karpolax, have developed a plant-based sachet that extends the shelf life of fresh fruit by up to 30 days. Their sustainable, biodegradable preservation solution has earned them a place in top 10 innovators in the Young Inventors Prize 2025, known as Tomorrow Shapers, which recognises young inventors tackling global challenges. They were selected from 450 candidates by an independent jury.
Sustainable preservation and fresher produce
Despite the steady increase in the global population, around 40% of all food produced does not reach the market, according to the World Wildlife Fund.
Namboozo and Muyita both grew up in farming families and saw first-hand the challenges of post-harvest losses, which have a devastating impact on the profit of small-scale farmers. Determined to find a natural and more affordable alternative to synthetic preservers, they developed sachets, which release a blend of plant-derived volatile organic compounds (VOCs) to slow ripening and prevent spoilage. The compounds – extracted from cloves, lemongrass, eucalyptus and wintergreen – inhibit ethylene production, the natural gas responsible for fruit ripening, and offer protection against mould, fungi and bacteria. Their solution allows for the controlled, sustained release of these compounds, tailored to different fruit types, thereby providing a biodegradable alternative to conventional artificial preservers.
Pilot tests conducted with Uganda's National Agricultural Research Organization showed that mangoes stored with the sachets remained fresh for 33 days, while those without them lasted only 11 days. The sachets have since been successfully used on bananas, apples, and oranges. With an affordable price point, Karpolax's sachets are particularly suited to smallholder farmers and local markets, offering a cost-effective and locally accessible way to reduce food waste and increase earnings.
Protecting innovation for lasting impact
"Farmers are one of our biggest customer groups. We wanted to use our knowledge and technical skills to develop something that would not just end on a paper in a lab but really be used by somebody," explains Namboozo.
The duo met while studying at Makerere University in Kampala, where they quickly bonded over a shared ambition to reduce food waste. They launched Karpolax in 2020 and aim to expand its reach across Africa, targeting Kenya, Rwanda and beyond. "Starting from zero, you need to source for that funding yourself. We had some supervisors from the university who supported us and made us feel confident that we could succeed," added Muyita.
By 2023, Karpolax had already worked with over 100 farmers, 20 exporters and 250 market vendors. The company is now expanding its product line to include sachets for pineapples, capsicum and berries.
The Young Inventors Prize celebrates worldwide innovators 30 and under using technology to address global challenges posed by the United Nations Sustainable Development Goals (SDGs). Namboozo and Muyita's work supports SDG 2 (Zero Hunger) by reducing post-harvest losses and SDG 12 (Responsible Consumption and Production) by promoting sustainable food preservation practices.
The prizes of the 2025 edition will be announced during a ceremony livestreamed from Iceland on 18 June 2025.
Find more information about the invention's impact, the technology and the inventor's story here.About the Young Inventors Prize
Aimed at individuals 30 and under, the Young Inventors Prize showcases the transformative power of youth-driven solutions and recognises the remarkable young people paving the way to a more sustainable future. Established in 2022, trophies were first handed out during the European Inventor Award ceremony. From 2025 onwards, the Prize will move up a gear with its own dedicated event, held separately from the Award. Among the 10 Tomorrow Shapers selected for each edition, three will be awarded a special prize: World Builders, Community Healers, and Nature Guardians. In addition, a People's Choice winner, voted by the public online, will be revealed. Each Tomorrow Shaper will receive EUR 5 000, the three special prize winners will each receive an extra EUR 15 000. The People's Choice winner will be awarded an additional EUR 5 000. Read more on the Young Inventors Prize eligibility and selection criteria.
About the EPO
With 6,300 staff members, the European Patent Office (EPO) is one of the largest public service institutions in Europe. Headquartered in Munich with offices in Berlin, Brussels, The Hague and Vienna, the EPO was founded with the aim of strengthening co-operation on patents in Europe. Through the EPO's centralised patent granting procedure, inventors are able to obtain high-quality patent protection in up to 46 countries, covering a market of some 700 million people. The EPO is also the world's leading authority in patent information and patent searching.
View original content:https://www.prnewswire.com/news-releases/extending-the-shelf-life-of-fruit-ugandan-entrepreneurs-sandra-namboozo-and-samuel-muyita-in-top-10-innovators-of-the-young-inventors-prize-2025-302452756.html
SOURCE European Patent Office (EPO)
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Business Insider
4 days ago
- Business Insider
CERo Therapeutics Holdings, Inc. Announces Continued Enhancement of Intellectual Property Portfolio with Two Granted U.S. Patents and European Patent Application Allowance Regarding Company's...
Results in 18 Issued Patents and Allowed Patent Applications Internationally with Nine Total Patent Families SOUTH SAN FRANSCISCO, Calif., June 02, 2025 (GLOBE NEWSWIRE) -- CERo Therapeutics Holdings, Inc., (Nasdaq: CERO) ('CERo' or the 'Company') an innovative immunotherapy company seeking to advance the next generation of engineered T cell therapeutics that deploy phagocytic (i.e., target-cell eating) mechanisms alongside the array of built-in target cell destroying mechanisms used by T cells, announces two previously announced U.S. patent applications have been granted by the U.S. Patent and Trademark Office (USPTO), and one European patent application has been allowed by the European Patent Office, all of which significantly expand the Company's intellectual property portfolio. The USPTO granted U.S. Patent No. 12,291,557, titled, 'CHIMERIC TIM4 RECEPTORS AND USES THEREOF' on May 6, 2025. The granted claims cover certain design aspects of CER-1236, the Company's lead compound. This patent provides composition of matter protection for a chimeric TIM4 receptor comprising a TIM4 binding domain and canonical T cell signaling domains. Additionally, the European Patent Office has allowed European Patent Application No. 1882166.7 titled, 'CHIMERIC ENGULFMENT RECEPTOR MOLECULES AND METHODS OF USE' on May 16, 2025. The allowed claims encompass a chimeric engulfment receptor comprising a TIM4 binding domain and TLR2 signaling domain. The allowance of this European patent application expands protection of additional design aspects of CER-1236, which have already been granted in the U.S., Japan, and China. Finally, the USPTO granted U.S. Patent No. 12,303,551, titled, 'CELLULAR IMMUNOTHERAPY COMPOSITIONS AND USES THEREOF,' on May 20, 2025. This patent provides coverage for combination cellular immunotherapy compositions and methods of use for CER-1236. The patent covers combination of a chimeric engulfment receptor CD4 + T cell (CD4 + CER-T cell) with a chimeric antigen receptor CD8 + T cell (CD8 + CAR-T cell) or T cell receptor CD8 + T cell (CD8 + TCR-T cell), and their use to treat cancer. This type of combination therapy could be an exciting avenue to complement the CER-T cell technology with other powerful anti-cancer therapies. CERo's intellectual property portfolio now includes 9 total patent families with protection out to 2042 in the United States. With these additional granted patents and allowed application, CER-1236 and its platform technology is supported by 18 total issued patents and allowed patent application internationally. Chris Ehrlich, CERo Therapeutics CEO, commented, 'We continue to aggressively expand our intellectual property portfolio, as it ensures CERo's success in the market. These patents protect the core innovations of the CER-T technology that differentiate it from other cell therapies and demonstrate the true novelty of our design . We continue to seek a robust range of patents across multiple geographies that cover this technology in general, and CER-1236 in particular. The appreciation of the novelty of the CER-T technology by the patent offices validates the innovation and therapeutic potential of this approach, and we believe that we will continue to grow the portfolio. In the near term, we anticipate updates on our clinical trial progress in AML, and the announcement of initiating human trials to treat ovarian and non-small cell lung cancers.' About CERo Therapeutics Holdings, Inc. CERo is an innovative immunotherapy company advancing the development of next generation engineered T cell therapeutics for the treatment of cancer. Its proprietary approach to T cell engineering, which enables it to integrate certain desirable characteristics of both innate and adaptive immunity into a single therapeutic construct, is designed to engage the body's full immune repertoire to achieve optimized cancer therapy. This novel cellular immunotherapy platform is expected to redirect patient-derived T cells to eliminate tumors by building in engulfment pathways that employ phagocytic mechanisms to destroy cancer cells, creating what CERo refers to as Chimeric Engulfment Receptor T cells ('CER-T'). CERo believes the differentiated activity of CER-T cells will afford them greater therapeutic application than currently approved chimeric antigen receptor ('CAR-T') cell therapy, as the use of CER-T may potentially span both hematological malignancies and solid tumors. CERo has commenced clinical trials for its lead product candidate CER-1236 for hematological malignancies. This communication contains statements that are forward-looking and as such are not historical facts. This includes, without limitation, statements regarding the financial position, business strategy and the plans and objectives of management for future operations of CERo. These statements constitute projections, forecasts and forward-looking statements, and are not guarantees of performance. Such statements can be identified by the fact that they do not relate strictly to historical or current facts. When used in this communication, words such as 'anticipate,' 'believe,' 'continue,' 'could,' 'estimate,' 'expect,' 'intend,' 'may,' 'might,' 'plan,' 'possible,' 'potential,' 'predict,' 'project,' 'should,' 'strive,' 'would' and similar expressions may identify forward-looking statements, but the absence of these words does not mean that a statement is not forward-looking. When CERo discusses its strategies or plans, it is making projections, forecasts or forward-looking statements. Such statements are based on the beliefs of, as well as assumptions made by and information currently available to, CERo's management. Actual results could differ from those implied by the forward-looking statements in this communication. Certain risks that could cause actual results to differ are set forth in CERo's filings with the Securities and Exchange Commission, including its most recent Annual Report on Form 10-K and subsequent Quarterly Reports on Form 10-Q, and the documents incorporated by reference therein. The risks described in CERo's filings with the Securities and Exchange Commission are not exhaustive. New risk factors emerge from time to time, and it is not possible to predict all such risk factors, nor can CERo assess the impact of all such risk factors on its business, or the extent to which any factor or combination of factors may cause actual results to differ materially from those contained in any forward-looking statements. Forward-looking statements are not guarantees of performance. You should not put undue reliance on these statements, which speak only as of the date hereof. All forward-looking statements made by CERo or persons acting on its behalf are expressly qualified in their entirety by the foregoing cautionary statements. CERo undertakes no obligation to update or revise publicly any forward-looking statements, whether as a result of new information, future events or otherwise, except as required by law.
Yahoo
02-06-2025
- Yahoo
CERo Therapeutics Holdings, Inc. Announces Continued Enhancement of Intellectual Property Portfolio with Two Granted U.S. Patents and European Patent Application Allowance Regarding Company's Lead Compound CER-1236
Results in 18 Issued Patents and Allowed Patent Applications Internationally with Nine Total Patent Families SOUTH SAN FRANSCISCO, Calif., June 02, 2025 (GLOBE NEWSWIRE) -- CERo Therapeutics Holdings, Inc., (Nasdaq: CERO) ('CERo' or the 'Company') an innovative immunotherapy company seeking to advance the next generation of engineered T cell therapeutics that deploy phagocytic (i.e., target-cell eating) mechanisms alongside the array of built-in target cell destroying mechanisms used by T cells, announces two previously announced U.S. patent applications have been granted by the U.S. Patent and Trademark Office (USPTO), and one European patent application has been allowed by the European Patent Office, all of which significantly expand the Company's intellectual property portfolio. The USPTO granted U.S. Patent No. 12,291,557, titled, 'CHIMERIC TIM4 RECEPTORS AND USES THEREOF' on May 6, 2025. The granted claims cover certain design aspects of CER-1236, the Company's lead compound. This patent provides composition of matter protection for a chimeric TIM4 receptor comprising a TIM4 binding domain and canonical T cell signaling domains. Additionally, the European Patent Office has allowed European Patent Application No. 1882166.7 titled, 'CHIMERIC ENGULFMENT RECEPTOR MOLECULES AND METHODS OF USE' on May 16, 2025. The allowed claims encompass a chimeric engulfment receptor comprising a TIM4 binding domain and TLR2 signaling domain. The allowance of this European patent application expands protection of additional design aspects of CER-1236, which have already been granted in the U.S., Japan, and China. Finally, the USPTO granted U.S. Patent No. 12,303,551, titled, 'CELLULAR IMMUNOTHERAPY COMPOSITIONS AND USES THEREOF,' on May 20, 2025. This patent provides coverage for combination cellular immunotherapy compositions and methods of use for CER-1236. The patent covers combination of a chimeric engulfment receptor CD4+ T cell (CD4+ CER-T cell) with a chimeric antigen receptor CD8+ T cell (CD8+ CAR-T cell) or T cell receptor CD8+ T cell (CD8+ TCR-T cell), and their use to treat cancer. This type of combination therapy could be an exciting avenue to complement the CER-T cell technology with other powerful anti-cancer therapies. CERo's intellectual property portfolio now includes 9 total patent families with protection out to 2042 in the United States. With these additional granted patents and allowed application, CER-1236 and its platform technology is supported by 18 total issued patents and allowed patent application internationally. Chris Ehrlich, CERo Therapeutics CEO, commented, 'We continue to aggressively expand our intellectual property portfolio, as it ensures CERo's success in the market. These patents protect the core innovations of the CER-T technology that differentiate it from other cell therapies and demonstrate the true novelty of our design . We continue to seek a robust range of patents across multiple geographies that cover this technology in general, and CER-1236 in particular. The appreciation of the novelty of the CER-T technology by the patent offices validates the innovation and therapeutic potential of this approach, and we believe that we will continue to grow the portfolio. In the near term, we anticipate updates on our clinical trial progress in AML, and the announcement of initiating human trials to treat ovarian and non-small cell lung cancers.' About CERo Therapeutics Holdings, Inc. CERo is an innovative immunotherapy company advancing the development of next generation engineered T cell therapeutics for the treatment of cancer. Its proprietary approach to T cell engineering, which enables it to integrate certain desirable characteristics of both innate and adaptive immunity into a single therapeutic construct, is designed to engage the body's full immune repertoire to achieve optimized cancer therapy. This novel cellular immunotherapy platform is expected to redirect patient-derived T cells to eliminate tumors by building in engulfment pathways that employ phagocytic mechanisms to destroy cancer cells, creating what CERo refers to as Chimeric Engulfment Receptor T cells ('CER-T'). CERo believes the differentiated activity of CER-T cells will afford them greater therapeutic application than currently approved chimeric antigen receptor ('CAR-T') cell therapy, as the use of CER-T may potentially span both hematological malignancies and solid tumors. CERo has commenced clinical trials for its lead product candidate CER-1236 for hematological malignancies. Forward-Looking Statements This communication contains statements that are forward-looking and as such are not historical facts. This includes, without limitation, statements regarding the financial position, business strategy and the plans and objectives of management for future operations of CERo. These statements constitute projections, forecasts and forward-looking statements, and are not guarantees of performance. Such statements can be identified by the fact that they do not relate strictly to historical or current facts. When used in this communication, words such as 'anticipate,' 'believe,' 'continue,' 'could,' 'estimate,' 'expect,' 'intend,' 'may,' 'might,' 'plan,' 'possible,' 'potential,' 'predict,' 'project,' 'should,' 'strive,' 'would' and similar expressions may identify forward-looking statements, but the absence of these words does not mean that a statement is not forward-looking. When CERo discusses its strategies or plans, it is making projections, forecasts or forward-looking statements. Such statements are based on the beliefs of, as well as assumptions made by and information currently available to, CERo's management. Actual results could differ from those implied by the forward-looking statements in this communication. Certain risks that could cause actual results to differ are set forth in CERo's filings with the Securities and Exchange Commission, including its most recent Annual Report on Form 10-K and subsequent Quarterly Reports on Form 10-Q, and the documents incorporated by reference therein. The risks described in CERo's filings with the Securities and Exchange Commission are not exhaustive. New risk factors emerge from time to time, and it is not possible to predict all such risk factors, nor can CERo assess the impact of all such risk factors on its business, or the extent to which any factor or combination of factors may cause actual results to differ materially from those contained in any forward-looking statements. Forward-looking statements are not guarantees of performance. You should not put undue reliance on these statements, which speak only as of the date hereof. All forward-looking statements made by CERo or persons acting on its behalf are expressly qualified in their entirety by the foregoing cautionary statements. CERo undertakes no obligation to update or revise publicly any forward-looking statements, whether as a result of new information, future events or otherwise, except as required by law. Contact:Chris EhrlichChief Executive Officerchris@ Investors:CORE IRinvestors@
Scientific American
29-05-2025
- Scientific American
These Climbers Summited Mount Everest in Record Time. Did Inhaling Xenon Help?
Last week a quartet of British climbers made it to the top of Mount Everest —and spent less than a week on the total round trip from London. That's weeks fewer than it usually takes to acclimate to the high elevation, scale the world's highest peak and head home. Their guide, speaking to the New York Times, credited their accomplishment to a secret advantage: prior to the trip, the climbers inhaled xenon gas, which may have made their acclimatization to the low-oxygen environment of Everest easier. But experts on the medical uses of xenon are uncertain that it was a decisive factor. 'Maybe there is something there. We just don't know,' says Andrew Subudhi, a professor of human physiology and nutrition at the University of Colorado Colorado Springs, who studies human performance in low-oxygen environments. 'From the scientific evidence, I can't see anything that is definitive or even proof-of-concept yet.' On supporting science journalism If you're enjoying this article, consider supporting our award-winning journalism by subscribing. By purchasing a subscription you are helping to ensure the future of impactful stories about the discoveries and ideas shaping our world today. How does xenon work in the body? Xenon is a noble gas—colorless, odorless, inert. But it does affect the body. It's been used as an anesthetic on occasion since the 1950s, says Robert Dickinson, a senior lecturer in medicine at Imperial College London. Dickinson has long studied another intriguing aspect of xenon: the gas has shown neuroprotective effects after a brain injury such as a stroke or a traumatic blow to the head. This protective quality has been demonstrated in many animal studies and a handful of small human trials, Dickinson says. Both the anesthetic and potential neuroprotective effects occur because xenon can bind to brain receptors called N-methyl-D-aspartate (NMDA) receptors. Activating these receptors has an excitatory effect on neurons, but xenon tamps down NMDA activity. After a brain injury, NMDA receptors can become overexcited, causing further cell death, so quieting these receptors might prevent additional damage. Those are xenon's best-studied effects on human health. But the gas has also piqued interest in the sports medicine world because it can increase the production of erythropoietin (EPO), a hormone that is known to stimulate the bone marrow to increase its production of red blood cells. Red blood cells carry oxygen, which is, of course, in short supply on the icy slopes of Mount Everest. Can xenon really acclimate someone to high elevations? Before attempting Everest's summit, climbers must hang out in Kathmandu, Nepal, and then Everest Base Camp for weeks, lest they fall prey to altitude sickness, which is marked by fatigue, headache, nausea and confusion. In serious cases, the lungs fill with fluid or the brain swells, which can quickly lead to death. The air at Everest Base Camp contains about half the oxygen as is present at sea level, and the air at the summit contains a mere 33 percent. Xenon's potential to increase the production of red blood cells, thus increasing the blood's ability carry oxygen, raises the question of whether it might provide a performance boost or prevent altitude sickness in the athletes climbing the world's highest peaks. The problem is: no one really knows if the EPO boost provided by xenon is enough to make a real difference in how someone handles a high elevation. Davide Cattano, an anesthesiologist at the McGovern Medical School at the University of Texas Health Science Center at Houston, did some of the animal research that has shown that xenon increases a blood factor called hypoxia-inducible factor 1–alpha (HIF-1α), which in turn can increase EPO. He's skeptical that the recent Everest climbers saw much benefit. 'The level of HIF that you're inducing does not justify this superhuman capability,' Cattano says. One 2019 study published in the Journal of Applied Physiology tested 12 runners who were randomly assigned to inhale air that contained 70 percent xenon or a sham gas for two minutes each day for several weeks before they ran three kilometers. The runners who inhaled xenon saw an increase in EPO in their blood, but they didn't show any improvement in fitness or athletic performance, as measured by their running speed and their heart rate and respiration during exercise. Even dosing people with EPO directly with injections may not prevent altitude sickness or improve performance at high elevation, Subudhi says. In a study that is currently in review for publication in a scientific journal, he and his colleagues tested EPO injections on a small group of mountain-climbing athletes, and these subjects didn't see any benefits. It's possible a different dose or a longer course of treatment might make a difference, Subudhi says, but 'my enthusiasm for chasing that is much less when I didn't see anybody have a measurable benefit.' Why did the recent Everest climbers reach the peak so quickly? It is possible xenon improved the climbers' oxygen-carrying capacity by boosting their EPO, experts say. It's also possible the anesthetic and analgesic effects of the gas ameliorated the climbers' aches and pains or the fatigue from altitude, Cattano speculates. Just the act of breathing a heavy gas like xenon might also result in some change to lung capacity, he says, even if the EPO effect is small. But the athletes also did something else: they slept in hypoxic tents for weeks before traveling to the mountain. These tents create a low-oxygen environment, which definitely increases EPO and red blood cell production. This preacclimatization, plus the climbers' intensive training regime, may have done the trick. Whether the xenon added any benefit on top of the hypoxic tents is unclear, Dickinson says. Xenon is expensive, which has limited its use as an anesthetic and in athletics. But more people will probably shell out for the gas, given that the baseline cost of climbing Mount Everest is so expensive and the stakes are so high, Subudhi says. 'People are literally fighting for their lives at high altitudes, and if you're doing things that may give you a small chance of improving your rate of success, yeah, it might be worth it to some people,' he says. 'Not everybody is going to sit there and make a completely scientific decision about their life.'
